Comparative Pharmacology
Head-to-head clinical analysis: PHENYLBUTAZONE versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLBUTAZONE versus PROFENAL.
PHENYLBUTAZONE vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."